Article

Beyond Seizures: Exploring Cannabidiol in Dravet Syndrome

Priscilla Simon1, Nair Shreedharsini Rajagopalan1, Fathima Jahnas1, Farhana Sudheer1, Mohammed Ameen Pattambi1, Sai Keerthana Puthiyedath Cheruvatta1

  1. 1Department of Pharmacy Practice, Al Shifa College of Pharmacy, Perinthalmanna, Malappuram, Kerala, INDIA.

CORRESPONDENCE

Sai Keerthana Puthiyedath Cheruvatta

saikeerthana2022@gmail.com

Received: 04-10-2024; Revised: 16-11-2024; Accepted: 17-12-2024.

Volume 13, Issue 3 · pp. 885–889 · PUBLISHED · DOI: 10.5530/ajbls.2024.13.106

View on AJBLS original site ↗

ABSTRACT

Aim: Dravet Syndrome (DS) is a severe epileptic and developmental encephalopathy causing drug-resistant seizures and developmental delay; this report presents two infant cases and evaluates CBD as adjunct therapy. Materials and Methods: Clinical case details, genetic testing (SCN1A) and treatment response were recorded and monitored. Results: Cannabidiol (CBD) added to regimens provided improved seizure control in refractory cases, with noted adverse effects including somnolence and GI upset. Conclusion: CBD may be beneficial for seizure control in DS but requires careful monitoring and further research on pediatric dosing.

KEYWORDS

Open in new tab

REFERENCES

As published

Showing references and in-text citations exactly as published.

    Cite this article

    SELECT FORMAT

    Simon, P., Rajagopalan, N. S., Jahnas, F., Sudheer, F., Pattambi, M. A., & Cheruvatta, S. K. P. (). Beyond Seizures: Exploring Cannabidiol in Dravet Syndrome. Asian Journal of Biological and Life sciences, 13(3), 885–889. https://doi.org/10.5530/ajbls.2024.13.106